Skip to main content
Erschienen in: Endocrine 2/2018

31.05.2017 | Clinical Management of Endocrine Diseases

Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study

verfasst von: S. Chiloiro, F. Lanza, A. Bianchi, G. Schinzari, M. G. Brizi, A. Giampietro, V. Rufini, F. Inzani, A. Giordano, G. Rindi, A. Pontecorvi, L. De Marinis

Erschienen in: Endocrine | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Multiple endocrine neoplasia type 1 (MEN1) is an inherited endocrine neoplastic syndrome associated with a greater risk of endocrine tumor development like pancreatic neuroendocrine tumors (p-NET), with different clinical characteristics from sporadic ones. This paper aims to compare clinical, hystological and morphological aspects of p-NET in patients affected from MEN1 (MEN1+) and not-affected ones (MEN1−).

Methods

We performed a retrospective observational study. Data was collected between December 2010 and December 2015, including patients with a histological diagnosis of p-NET and radiological imaging. We compared clinical, histological, radiological, and prognostic aspects of MEN+ p-NET with MEN−1 p-NET.

Results

Of the 45 patients enrolled, 13 MEN1+ and 21 MEN1− cases were analyzed. Frequency of not secreting p-NETs and insulin secreting p-NETs, histopathological grades and Ki67 expression were superimposable between MEN1+ and MEN1− patients. MEN1+ pNETs are more often multicentric compared to MEN1− pNETs. Frequency of liver and nodes metastatic spread was higher in MEN1− p-NET compared to MEN1+ p-NET. Analyzing p-NET according to the disease outcome, we found that recovered and stable p-NETs in MEN1+ patients, compared to MEN1− cases, are diagnosed at lower age (p = 0.04/p = 0.002) and that are more frequently multifocal lesions (p = 0.009/p = 0.002).

Conclusions

In our study pNETs in MEN1+ and pNETs in MEN1− don’t significantly differ for prognosis but only for clinical features. p-NET stage disease and prognosis can be positively influenced by early diagnosis and screening in index patients’ first-degree relatives
Literatur
1.
Zurück zum Zitat P. Wermer, Genetic aspects of adenomatosis of endocrine glands. Am. J. Med. 16, 363–371 (1954)CrossRefPubMed P. Wermer, Genetic aspects of adenomatosis of endocrine glands. Am. J. Med. 16, 363–371 (1954)CrossRefPubMed
2.
Zurück zum Zitat P. Wermer, Endocrine adenomatosis, peptic ulcer disease in a large kindred: inherited multiple tumors, mosaic pleiotropism in man. Am. J. Med. 35, 205–208 (1963)CrossRefPubMed P. Wermer, Endocrine adenomatosis, peptic ulcer disease in a large kindred: inherited multiple tumors, mosaic pleiotropism in man. Am. J. Med. 35, 205–208 (1963)CrossRefPubMed
3.
Zurück zum Zitat A. Sakurai, S. Suzuki, S. Kosugi, T. Okamoto, S. Uchino, A. Miya et al., Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of multicenter database. Clin. Endocrinol. 76(4), 533–539 (2012)CrossRef A. Sakurai, S. Suzuki, S. Kosugi, T. Okamoto, S. Uchino, A. Miya et al., Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of multicenter database. Clin. Endocrinol. 76(4), 533–539 (2012)CrossRef
4.
Zurück zum Zitat J.M. Glascock, S.E. Carty, Multiple endocrine neoplasia type 1: fresh perspective on clinical features and penetrance. Surg. Oncol. 11, 143–150 (2002)CrossRefPubMed J.M. Glascock, S.E. Carty, Multiple endocrine neoplasia type 1: fresh perspective on clinical features and penetrance. Surg. Oncol. 11, 143–150 (2002)CrossRefPubMed
5.
Zurück zum Zitat S.L. Dʼsouza, B.J. Elmunzer, J.M. Scheiman, Long-term follow-up of asymptomatic pancreatic neuroendocrine tumors in multiple endocrine neoplasia type I syndrome. J. Clin. Gastroenterol. 48(5), 458–461 (2014)PubMed S.L. Dʼsouza, B.J. Elmunzer, J.M. Scheiman, Long-term follow-up of asymptomatic pancreatic neuroendocrine tumors in multiple endocrine neoplasia type I syndrome. J. Clin. Gastroenterol. 48(5), 458–461 (2014)PubMed
6.
Zurück zum Zitat F. Gibril, D.J. Venzon, J.V. Ojeburu, S. Bashir, R.T. Jensen, Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J. Clin. Endocrinol. Metab. 86(11), 5282–5293 (2001)CrossRefPubMed F. Gibril, D.J. Venzon, J.V. Ojeburu, S. Bashir, R.T. Jensen, Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J. Clin. Endocrinol. Metab. 86(11), 5282–5293 (2001)CrossRefPubMed
7.
Zurück zum Zitat G. Åkerström, O. Hessman, B. Skogseid, Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbeck’s Arch Surg 386, 558–569 (2002)CrossRef G. Åkerström, O. Hessman, B. Skogseid, Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbeck’s Arch Surg 386, 558–569 (2002)CrossRef
8.
Zurück zum Zitat G. Rindi, R. Arnold, C. Capella, et al. in Nomenclature and Classification of Neuroendocrine Neoplasms of the Digestive System, ed. by F. Bosman, F. Carneiro. World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of the Digestive System (Lyon, IARC Press, 2010), p. 10–12. G. Rindi, R. Arnold, C. Capella, et al. in Nomenclature and Classification of Neuroendocrine Neoplasms of the Digestive System, ed. by F. Bosman, F. Carneiro. World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of the Digestive System (Lyon, IARC Press, 2010), p. 10–12.
9.
Zurück zum Zitat G. Klöppel, G. Rindi, A. Perren, P. Komminoth, D.S. Klimstra, The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows. Arch. 456, 595–597 (2010)CrossRefPubMed G. Klöppel, G. Rindi, A. Perren, P. Komminoth, D.S. Klimstra, The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows. Arch. 456, 595–597 (2010)CrossRefPubMed
10.
Zurück zum Zitat R.V. Thakker, P.J. Newey, G.V. Walls, J. Bilezikian, H. Dralle, P.R. Ebeling, S. Melmed, A. Sakurai, F. Tonelli, M.L. Brandi, Clinical practice guidelines for multiple endocrine Neoplasia type 1 (MEN1). J. Clin. Endocrinol. Metab. 97, 2990–3011 (2012)CrossRefPubMed R.V. Thakker, P.J. Newey, G.V. Walls, J. Bilezikian, H. Dralle, P.R. Ebeling, S. Melmed, A. Sakurai, F. Tonelli, M.L. Brandi, Clinical practice guidelines for multiple endocrine Neoplasia type 1 (MEN1). J. Clin. Endocrinol. Metab. 97, 2990–3011 (2012)CrossRefPubMed
11.
Zurück zum Zitat A. Zerbi, M. Falconi, G. Rindi, G. Delle Fave, P. Tomassetti, C. Pasquali, V. Capitanio, L. Boninsegna, V. Di Carlo; the members of the AISP-Network Study Group, Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 Sporadic Cases. Am. J. Gastroenterol. 105, 1421–1429 (2010)CrossRefPubMed A. Zerbi, M. Falconi, G. Rindi, G. Delle Fave, P. Tomassetti, C. Pasquali, V. Capitanio, L. Boninsegna, V. Di Carlo; the members of the AISP-Network Study Group, Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 Sporadic Cases. Am. J. Gastroenterol. 105, 1421–1429 (2010)CrossRefPubMed
12.
Zurück zum Zitat A. Zerbi, V. Capitanio, L. Boninsegna, G. Delle Fave, C. Pasquali, G. Rindi, D. Campana, M. Falconi; the members of the AISP-Network Study Group, Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. HPB 15, 935–943 (2013)CrossRefPubMedPubMedCentral A. Zerbi, V. Capitanio, L. Boninsegna, G. Delle Fave, C. Pasquali, G. Rindi, D. Campana, M. Falconi; the members of the AISP-Network Study Group, Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. HPB 15, 935–943 (2013)CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, L. Rubinstein et al., New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92, 205–216 (2000)CrossRefPubMed P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, L. Rubinstein et al., New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92, 205–216 (2000)CrossRefPubMed
14.
Zurück zum Zitat B. Skögseid, J. Rastad, G. Akerström. Pancreatic Endocrine Tumors in Multiple Endocrine Neo- plasia Type 1. Surgical Endocrinology, ed. by G.M. Doherty, B. Skögseid (Lippincott, Williams & Wilkins, Philadelphia, 2001) p. 510–524 B. Skögseid, J. Rastad, G. Akerström. Pancreatic Endocrine Tumors in Multiple Endocrine Neo- plasia Type 1. Surgical Endocrinology, ed. by G.M. Doherty, B. Skögseid (Lippincott, Williams & Wilkins, Philadelphia, 2001) p. 510–524
15.
Zurück zum Zitat R.T. Jensen. Zollinger-Ellison syndrome. Surgical Endocrinology, ed. by G.M. Doherty, B. Skögseid (Lippincott, Williams & Wilkins, Philadelphia, 2001) 291–344 R.T. Jensen. Zollinger-Ellison syndrome. Surgical Endocrinology, ed. by G.M. Doherty, B. Skögseid (Lippincott, Williams & Wilkins, Philadelphia, 2001) 291–344
16.
Zurück zum Zitat K. Hanazaki, A. Sakurai, M. Munekage, K. Ichikawa, T. Namikawa, T. Okabayashi, M. Imamura, Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1. Surg. Today 43(3), 229–236 (2013)CrossRefPubMed K. Hanazaki, A. Sakurai, M. Munekage, K. Ichikawa, T. Namikawa, T. Okabayashi, M. Imamura, Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1. Surg. Today 43(3), 229–236 (2013)CrossRefPubMed
17.
Zurück zum Zitat F. Tonelli, F. Giudici, G. Fratini, M.L. Brandi, Pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: review of literature. Endocr. Pract. 17(suppl 3), 33–40 (2011) F. Tonelli, F. Giudici, G. Fratini, M.L. Brandi, Pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: review of literature. Endocr. Pract. 17(suppl 3), 33–40 (2011)
18.
Zurück zum Zitat P.V. Dickson, T.A. Rich, Y. Xing, G.J. Cote, H. Wang, N.D. Perrier et al., Achieving eugastrinemia in MEN1 patients: both duodenal inspection and formal lymph node dissection are important. Surgery 150, 1143–1152 (2011)CrossRefPubMed P.V. Dickson, T.A. Rich, Y. Xing, G.J. Cote, H. Wang, N.D. Perrier et al., Achieving eugastrinemia in MEN1 patients: both duodenal inspection and formal lymph node dissection are important. Surgery 150, 1143–1152 (2011)CrossRefPubMed
19.
Zurück zum Zitat M.L. Brandi, R.F. Gagel, A. Angeli, J.P. Bilezikian, P. Beck-Peccoz, C. Bordi, B. Conte-Devolx, A. Falchetti, R.G. Gheri, A. Libroia, C.J.M. Lips, G. Lombardi, M. Mannelli, F. Pacini, B.A.J. Ponder, F. Raue, B. Skogseid, G. Tamburrano, R.V. Thakker, N.W. Thompson, P. Tomassetti, F. Tonelli, S.A. Wells, Jr., S.J. Marx, Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86(12), 5658–5671 (2001) M.L. Brandi, R.F. Gagel, A. Angeli, J.P. Bilezikian, P. Beck-Peccoz, C. Bordi, B. Conte-Devolx, A. Falchetti, R.G. Gheri, A. Libroia, C.J.M. Lips, G. Lombardi, M. Mannelli, F. Pacini, B.A.J. Ponder, F. Raue, B. Skogseid, G. Tamburrano, R.V. Thakker, N.W. Thompson, P. Tomassetti, F. Tonelli, S.A. Wells, Jr., S.J. Marx, Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86(12), 5658–5671 (2001)
20.
Zurück zum Zitat M. Vázquez, S. Muñoz, L. López, C. Hernández, J. Navalón, Diagnostic/therapeutic management of pancreatic neuroendocrine tumours associated with MEN 1 syndrome. Cir. Esp. 93(8), 539–541 (2015)CrossRef M. Vázquez, S. Muñoz, L. López, C. Hernández, J. Navalón, Diagnostic/therapeutic management of pancreatic neuroendocrine tumours associated with MEN 1 syndrome. Cir. Esp. 93(8), 539–541 (2015)CrossRef
21.
Zurück zum Zitat F. Triponez, D. Dosseh, P. Goudet et al., Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann. Surg. 243, 265–272 (2006)CrossRefPubMedPubMedCentral F. Triponez, D. Dosseh, P. Goudet et al., Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann. Surg. 243, 265–272 (2006)CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat R.B. Lewis, G.E. Lattin Jr., E. Paal, Endocrine tumors: Radiologic- clinicopathologic correlation. Radiographics 30(6), 1445–1464 (2010)CrossRefPubMed R.B. Lewis, G.E. Lattin Jr., E. Paal, Endocrine tumors: Radiologic- clinicopathologic correlation. Radiographics 30(6), 1445–1464 (2010)CrossRefPubMed
23.
Zurück zum Zitat L. Boninsegna, S. Partelli, M.M. D’Innocenzio, P. Capelli, A. Scarpa, C. Bassi, P. Pederzoli, M. Falconi, Pancreatic cystic endocrine tumors: a different morphological entity associated with a less aggressive behavior. Neuroendocrinology 92(4), 246–251 (2010)CrossRefPubMed L. Boninsegna, S. Partelli, M.M. D’Innocenzio, P. Capelli, A. Scarpa, C. Bassi, P. Pederzoli, M. Falconi, Pancreatic cystic endocrine tumors: a different morphological entity associated with a less aggressive behavior. Neuroendocrinology 92(4), 246–251 (2010)CrossRefPubMed
25.
Zurück zum Zitat U. Plöckinger, B. Wiedenman, Neuroendocrine tumors of the gastro-entero-pancreatic system: the role of early diagnosis, genetic testing and preventive surgery. Dig. Dis. 20, 49–60 (2002)CrossRefPubMed U. Plöckinger, B. Wiedenman, Neuroendocrine tumors of the gastro-entero-pancreatic system: the role of early diagnosis, genetic testing and preventive surgery. Dig. Dis. 20, 49–60 (2002)CrossRefPubMed
26.
Zurück zum Zitat K. Drbalová, K. Herdová, P. Krejčí, M. Nývltová, S. Solař, L. Vedralová, P. Záruba, D. Netuka, P. Bavor, [Multiple Endocrine Neoplasia I (Wermers Syndrome), Forms of Clinical Manifestation, 5 Case Studies]. Vnitr. Lek. 62(Suppl 3), 140–149 (2016)PubMed K. Drbalová, K. Herdová, P. Krejčí, M. Nývltová, S. Solař, L. Vedralová, P. Záruba, D. Netuka, P. Bavor, [Multiple Endocrine Neoplasia I (Wermers Syndrome), Forms of Clinical Manifestation, 5 Case Studies]. Vnitr. Lek. 62(Suppl 3), 140–149 (2016)PubMed
27.
Zurück zum Zitat M.S. Hausman, Jr., N.W. Thompson, P.G. Gauger, G.M. Doherty, The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. Surgery 136, 1205–1211 (2004) M.S. Hausman, Jr., N.W. Thompson, P.G. Gauger, G.M. Doherty, The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. Surgery 136, 1205–1211 (2004)
28.
Zurück zum Zitat T. Ito, H. Sasano, M. Tanaka, R.Y. Osamura, I. Sasaki et al., Epidemiological study of gastroenteropan- creatic neuroendocrine tumors in Japan. J. Gastroenterol. 45, 234–243 (2010)CrossRefPubMed T. Ito, H. Sasano, M. Tanaka, R.Y. Osamura, I. Sasaki et al., Epidemiological study of gastroenteropan- creatic neuroendocrine tumors in Japan. J. Gastroenterol. 45, 234–243 (2010)CrossRefPubMed
29.
Zurück zum Zitat R. Casadei, C. Ricci, R. Pezzilli, D. Campana, P. Tomassetti, L. Calculli, D. Santini, M. D’Ambra, F. Minni, Are there prognostic factors related to recurrence in pancreatic endocrine tumors? Pancreatology 10(1), 33–38 (2010)CrossRefPubMed R. Casadei, C. Ricci, R. Pezzilli, D. Campana, P. Tomassetti, L. Calculli, D. Santini, M. D’Ambra, F. Minni, Are there prognostic factors related to recurrence in pancreatic endocrine tumors? Pancreatology 10(1), 33–38 (2010)CrossRefPubMed
30.
Zurück zum Zitat D. Granberg, M. Stridsberg, R. Seensalu, B. Eriksson, G. Lundqvist, K.O ̈ Berg, B. Skogseid, Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. CE & M. 84, (8), 2712–2717 (1999) D. Granberg, M. Stridsberg, R. Seensalu, B. Eriksson, G. Lundqvist, K.O ̈ Berg, B. Skogseid, Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. CE & M. 84, (8), 2712–2717 (1999)
31.
Zurück zum Zitat I.M. Modlin, B.I. Gustafsson, S.F. Moss, M. Pavel, A.V. Tsolakis, M. Kidd, Chromogranin A—Biological function and clinical utility in neuro endocrine tumor disease. Ann. Surg. Oncol. 17, 2427–2443 (2010)CrossRefPubMed I.M. Modlin, B.I. Gustafsson, S.F. Moss, M. Pavel, A.V. Tsolakis, M. Kidd, Chromogranin A—Biological function and clinical utility in neuro endocrine tumor disease. Ann. Surg. Oncol. 17, 2427–2443 (2010)CrossRefPubMed
32.
Zurück zum Zitat B. Lawrence, B.I. Gustafsson, M. Kidd, M. Pavel, B. Svejda, I.M. Modlin, The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am 40, 111–134 (2011)CrossRef B. Lawrence, B.I. Gustafsson, M. Kidd, M. Pavel, B. Svejda, I.M. Modlin, The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am 40, 111–134 (2011)CrossRef
33.
Zurück zum Zitat E. Bajetta, L. Ferrari, A. Martinetti, L. Celio, G. Procopio, S. Artale, N. Zilembo, M. Di Bartolomeo, E. Seregni, E. Bombardieri, Chromogranin A., neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer, 86(5), 858–865 (1999) E. Bajetta, L. Ferrari, A. Martinetti, L. Celio, G. Procopio, S. Artale, N. Zilembo, M. Di Bartolomeo, E. Seregni, E. Bombardieri, Chromogranin A., neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer, 86(5), 858–865 (1999)
34.
Zurück zum Zitat S. Gaztambide, F. Vazquez, L. Castaño, Diagnosis and treatment of multiple endocrine neoplasia type 1 (MEN1). Minerva. Endocrinol. 38(1), 17–28 (2013)PubMed S. Gaztambide, F. Vazquez, L. Castaño, Diagnosis and treatment of multiple endocrine neoplasia type 1 (MEN1). Minerva. Endocrinol. 38(1), 17–28 (2013)PubMed
35.
Zurück zum Zitat Ita.NET Guidelines if Neuroendocrine Neoplasia. 2015 Edition Ita.NET Guidelines if Neuroendocrine Neoplasia. 2015 Edition
Metadaten
Titel
Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study
verfasst von
S. Chiloiro
F. Lanza
A. Bianchi
G. Schinzari
M. G. Brizi
A. Giampietro
V. Rufini
F. Inzani
A. Giordano
G. Rindi
A. Pontecorvi
L. De Marinis
Publikationsdatum
31.05.2017
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2018
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1327-0

Weitere Artikel der Ausgabe 2/2018

Endocrine 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.